QIAGEN powered by

 

Looking for a comprehensive way to evaluate myeloid malignancies?

 

QCI Interpret
for Myeloid Malignancies

 

 

 

Defining the clinical impact of NGS markers for different myeloid entities is becoming increasingly complex.

Myeloid malignancies are clinically heterogeneous diseases.

They develop from benign neoplasms to malignant tumors in different ways, and actionability often depends on the etiology of the cancer. To provide a comprehensive diagnostic and prognostic assessment of myeloid malignancies, hematologist-oncologists and molecular pathologists need to combine and consider clinical, cytogenetic and molecular genetic findings.

Upcoming Event: Meet QIAGEN at ASH 2019

The premier event in malignant and non-malignant hematology, the 61st Annual American Society of Hematology (ASH) Meeting will take place December 7-10, at the Orange County Convention Center in Orlando, Florida.

Ask our experts at booth #2453 about QCI Interpret for Myeloid Malignancies and receive a hands-on demonstration.

 


QCI Interpret for Myeloid Malignancies integrates data from multiple diagnostic and prognostic analyses into one actionable report.

 

Enable comprehensive clinical NGS analysis and reporting.

QCI automatically incorporates prognostic actionability criteria supporting tier classifications of the AMP/ASCO/CAP Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer, as well as cytogenetic results and the variant’s somatic frequency across World Health Organization (WHO)-reported hematological cancers.

Integrate diverse content sources for variant interpretation and reporting.

The QIAGEN Knowledge Base stands as an interconnected and interdependent network of structured data built by MD and PhD certified content curation specialists. With one click, you receive information on the variant’s characteristics, active clinical trial registries, available drug therapies, and prognostic insights on over 1,100 curated alteration types associated with myeloid malignancies.

Accelerate time from sequence to report.

Implement a full workflow for variant calling through pre-configured, comprehensive and expandable NGS secondary data analysis pipelines that take you from FASTQ to VCF with greater speed, accuracy and confidence. QCI Analyze Universal is the companion product to QCI Interpret that allows you to confidently identify variants from your NGS tests.


.
 
 
 
 
.
 
 
 
 
.
 
 
 
 
.
 
 
 
 
.
 
 
 
 
.
 
 
 
 
.
 
 
 
 
.
 
 
 


VIEW SAMPLE REPORT

 
 

Try QCI Interpret for Myeloid Malignancies

Request your free, no obligation, demonstration of QCI Interpret for Myeloid Malignancies today.

 

 

*QIAGEN Clinical Insight (QCI) is an evidence-based decision support software intended as an aid in the interpretation of variants observed in genomic sequencing data. The software evaluates genomic variants in the context of published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels, and clinical-trials. Based on this evaluation, the software proposes a classification to aid in the interpretation of observed variants. The software is NOT intended as a primary diagnostic tool by physicians or to be used as a substitute for professional healthcare advice. Each laboratory is responsible for ensuring compliance with applicable international, national, and local clinical laboratory regulations and other specific accreditations requirements.